FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
Follows Japanese Approval Last September
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
